Case Note & Summary
The Appellant, SaNOtize Research and Development Corp., a Canadian corporation, filed a Commercial Appeal against an order dated 21st October 2021 dismissing its Interim Application for an injunction against the Respondents, Lupin Limited and others, from manufacturing, selling, or dealing with a nasal spray called NOXGUARD. The Appellant claimed that NOXGUARD was developed using its confidential information in breach of a Confidentiality Agreement dated 17th May 2021 entered into between the Appellant and Lupin. The Appellant sought to restrain the Respondents from dealing with NOXGUARD, which was marketed as an advanced nasal spray releasing nitric oxide from natural sources and killing 99.99% of viruses within 2 minutes. The court examined the terms of the Confidentiality Agreement and the alleged confidential information. The court noted that the Appellant had not specifically identified the confidential information that was allegedly misused, nor had it demonstrated that such information was imparted to the Respondents under an obligation of confidence. The court also considered the balance of convenience and irreparable loss, finding that the Appellant had not made out a prima facie case for an injunction. The court dismissed the appeal, holding that the Appellant failed to establish that the Respondents had used its confidential information in developing NOXGUARD. The court emphasized that the burden of proof lies on the party alleging breach of confidence to specifically identify the confidential information and show that it was imparted under an obligation of confidence and subsequently misused. The court found that the Appellant did not discharge this burden and that the balance of convenience did not favor granting an injunction.
Headnote
A) Intellectual Property - Confidential Information - Breach of Confidentiality Agreement - Prima Facie Case - The court considered whether the Appellant had established a prima facie case that the Respondents misused its confidential information in developing NOXGUARD. The court held that the Appellant failed to show that the information allegedly misused was covered by the Confidentiality Agreement dated 17th May 2021, and that the balance of convenience did not favor granting an injunction. (Paras 1-10) B) Civil Procedure - Interim Injunction - Principles for Grant - The court reiterated the settled principles for grant of interim injunction: existence of a prima facie case, balance of convenience in favor of the plaintiff, and irreparable loss not compensable by damages. The court found that the Appellant did not satisfy these requirements. (Paras 11-20) C) Evidence - Confidential Information - Burden of Proof - The court held that the burden lies on the party alleging breach of confidence to specifically identify the confidential information and demonstrate that it was imparted under an obligation of confidence and subsequently misused. The Appellant failed to discharge this burden. (Paras 21-30)
Issue of Consideration
Whether the Appellant made out a prima facie case for grant of an interim injunction restraining the Respondents from manufacturing, selling, or dealing with the nasal spray NOXGUARD on the ground that it was developed using Appellant's confidential information in breach of a Confidentiality Agreement.
Final Decision
Appeal dismissed. The order dated 21st October 2021 dismissing the Interim Application and vacating the ad interim order is upheld.
Law Points
- Confidentiality Agreement
- Breach of Confidence
- Prima Facie Case
- Balance of Convenience
- Irreparable Loss
- Interim Injunction
- Trade Secret
